Business Context and Reporting Period
Sana Biotechnology, Inc. (SANA) is a biotechnology company developing engineered cell therapies for Type 1 diabetes, B-cell cancers, and autoimmune diseases. This Form 10-Q covers the quarterly period ended September 30, 2025. The company operates as an emerging growth company and is currently in the development stage with no approved products for commercial sale.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(42.2) million | $(59.9) million | $(185.3) million | $(217.7) million |
| Loss Per Share (Basic/Diluted) | $(0.16) | $(0.25) | $(0.75) | $(0.95) |
| Operating Expenses | $43.5 million | $61.8 million | $189.1 million | $221.9 million |
| Cash & Cash Equivalents | $103.4 million | $127.6 million (Dec 31, 2024) | As of Sept 30, 2025 | |
| Marketable Securities | $49.7 million | $24.9 million (Dec 31, 2024) | As of Sept 30, 2025 | |
| Total Liquidity (Cash + Securities) | $153.1 million | $152.5 million (Dec 31, 2024) | As of Sept 30, 2025 | |
| Accumulated Deficit | $(1.79) billion | $(1.60) billion (Dec 31, 2024) | As of Sept 30, 2025 |
Material Changes vs. Prior Period
- Reduced Operating Expenses: Total operating expenses decreased by $18.2 million (29.5%) in Q3 2025 compared to Q3 2024, and by $32.7 million (14.7%) on a year-to-date basis. This reduction is primarily attributed to portfolio prioritization and workforce reductions announced in November 2024.
- Research & Development (R&D): R&D expenses dropped significantly to $30.1 million in Q3 2025 from $53.2 million in Q3 2024. The decrease is driven by lower headcount and the suspension of specific clinical trials (ARDENT) and programs (SC379).
- Impairment Charges: The company recognized a non-cash impairment loss of $44.6 million in the second quarter of 2025 related to long-lived assets (construction in progress, laboratory equipment, and leasehold improvements) at its Bothell and Seattle facilities. No impairment was recorded in Q3 2025.
- Success Payments & Contingent Consideration: Expenses related to the fair value changes of success payment liabilities and contingent consideration fluctuated. In Q3 2025, the company recorded a net expense of $3.1 million, compared to a net gain of $5.5 million in Q3 2024.
- Capital Raises: In August 2025, Sana completed an underwritten public offering raising approximately $80.6 million. Additionally, the company utilized its At-The-Market (ATM) facility to raise $28.6 million in Q3 2025.
Guidance, Outlook, and Risks
- Portfolio Prioritization: In November 2025, management announced a strategic shift to prioritize the SC451 (Type 1 diabetes) and SG293 (in vivo CAR T) programs. Consequently, development of the SC291 and SC262 allogeneic CAR T programs has been suspended.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($153.1 million as of Sept 30, 2025), combined with recent financing proceeds, are sufficient to fund operations for at least one year from the filing date.
- Manufacturing Strategy: The company has suspended further internal build-out of its manufacturing facility in Bothell, Washington, opting to rely on third-party Contract Development and Manufacturing Organizations (CDMOs) for the near term.
- Legal Proceedings: A putative securities class action lawsuit was filed in March 2025 alleging false statements regarding the company's business and prospects. The company filed a motion to dismiss in October 2025.
- Risk Factors: Key risks include the need for additional capital, the unproven nature of the company's novel technologies, potential failure of clinical trials, and significant contingent liabilities (up to $500 million for Cobalt milestones and $175 million for Harvard success payments) that fluctuate based on stock price and market capitalization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $153.1 million liquidity position against the burn rate, considering the suspension of internal manufacturing build-out.
- Impairment Details: Review Note 11 for specifics on the $44.6 million impairment charge and its impact on future depreciation and facility costs.
- Contingent Liabilities: Monitor the fair value of Cobalt and Harvard success payment liabilities, which are sensitive to stock price volatility and market cap thresholds.
- Clinical Progress: Track the status of the UP421 investigator-sponsored trial (positive 6-month data reported) and the planned IND filing for SC451 (expected 2026).
- Legal Status: Follow the progress of the securities class action litigation and the outcome of the motion to dismiss.